Pemvidutide

Human clinical Weight Loss & Metabolism 3 sources

Pemvidutide is a novel dual-agonist peptide targeting both GLP-1 and glucagon receptors. Research indicates it promotes significant weight loss while simultaneously reducing liver fat content, making it a promising candidate for treating obesity and metabolic dysfunction-associated steatohepatitis (MASH).

01Dosing reference

Amount

1.2 mg to 2.4 mg

Frequency

Once weekly

Cycle

Continuous weekly administration in clinical trials (e.g., 12 to 48 weeks)

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Dual Receptor Activation

Pemvidutide binds to and activates both the Glucagon-Like Peptide-1 (GLP-1) and glucagon receptors.

Metabolic Synergy

GLP-1 activation suppresses appetite and delays gastric emptying, while glucagon receptor activation increases energy expenditure and promotes hepatic fat mobilization.

Weight and Liver Fat Reduction

The combined effect leads to substantial reductions in body weight and significant decreases in liver fat content (LFC) and hepatic inflammation.

03Human evidence

Significant reductions in liver fat content (LFC) and body weight after 12-24 weeks of treatment.

Phase 1 and Phase 2 randomized, double-blind, placebo-controlled clinical trials in patients with obesity, overweight, and MASLD/MASH.

Improvements in markers of hepatic inflammation, such as serum ALT.

Observed in clinical trials assessing the efficacy of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).

04Preclinical evidence

Demonstrated potent weight loss and reduction in hepatic steatosis.

Animal models of diet-induced obesity and non-alcoholic fatty liver disease (NAFLD).

Synergistic effects of GLP-1 and glucagon agonism on energy expenditure and lipid metabolism.

In vitro and in vivo pharmacological profiling studies.

05What is known vs. unknown

Reasonably established

Pemvidutide is a dual agonist of GLP-1 and glucagon receptors.
It has shown efficacy in reducing both body weight and liver fat content in human trials.
It is currently under investigation for the treatment of obesity and MASH (metabolic dysfunction-associated steatohepatitis).
Administered via subcutaneous injection.

Unknowns & limits

Long-term safety and cardiovascular outcomes beyond the duration of current Phase 2 trials are not yet fully established.
The optimal dosing strategy to balance weight loss, liver fat reduction, and tolerability requires further refinement in Phase 3 trials.

06Safety & regulatory context

Regulatory statusPemvidutide is currently an investigational drug and is not FDA-approved for any indication. In clinical trials, it has generally been well-tolerated, with the most common side effects being gastrointestinal in nature (nausea, vomiting, diarrhea), similar to other GLP-1 receptor agonists. The addition of glucagon agonism raises theoretical concerns about heart rate increases or glycemic control issues, though trials aim to balance this with the GLP-1 component. It is being evaluated under FDA Investigational New Drug (IND) clearance.

07Compared with Semaglutide

Pemvidutide vs. Semaglutide

Key difference

Semaglutide is a selective GLP-1 receptor agonist, whereas pemvidutide is a dual agonist targeting both GLP-1 and glucagon receptors, potentially offering enhanced liver fat reduction and energy expenditure.

When researchers discuss each

Semaglutide is discussed as the standard-of-care GLP-1 agonist for weight loss and diabetes, while pemvidutide is discussed in the context of next-generation therapies aiming for superior efficacy in MASH and obesity through dual-receptor mechanisms.

08Glossary

GLP-1 Receptor Agonist

A class of drugs that mimic the incretin hormone GLP-1, stimulating insulin release, inhibiting glucagon secretion, and slowing gastric emptying to lower blood sugar and reduce appetite.

Glucagon Receptor Agonist

A substance that activates the glucagon receptor, typically leading to increased glucose production by the liver and enhanced lipid metabolism and energy expenditure.

MASH

Metabolic dysfunction-associated steatohepatitis, a severe form of liver disease characterized by inflammation and liver damage due to fat buildup.

09Knowledge check

Q1Which two receptors does pemvidutide target?

Q2In addition to weight loss, what significant hepatic benefit has pemvidutide demonstrated in clinical trials?

Q3Which limitation of the current pemvidutide clinical evidence is explicitly noted in the dossier and should be considered when interpreting trial results?

Q4In the dossier's stated comparison with semaglutide, what is the primary mechanistic distinction attributed to pemvidutide?

Q5Which statement best summarizes pemvidutide's regulatory status and the safety observations reported in the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.